Why AbbVie Stock Popped While the Market Flopped on Monday

Core Insights - AbbVie experienced a share price increase of nearly 4%, contrasting with the S&P 500's decline of 1.5% on the same day [1] - The price target increases from analysts were announced ahead of AbbVie's fourth-quarter earnings report scheduled for January 31 [2] Analyst Price Target Changes - Goldman Sachs raised its price target for AbbVie to $208 per share from$205, despite lowering some profitability estimates, while remaining optimistic about its immunology products [3] - Piper Sandler increased its price target to $227 per share from$220, citing similar reasons and highlighting a potential $3.5 billion noncash, after-tax impairment charge related to the investigational drug emraclidine [4] Company Strengths - AbbVie is recognized as a strong pharmaceutical stock, supported by a robust product lineup and a promising pipeline of developmental programs [5] - The company offers a generous dividend, which is notable in the pharmaceutical sector known for lower dividend payouts [5]